http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 16:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+May+18/26514823.html si-local-file:///var/storage/secattach/20260518/26514823.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+May+18/26514823.html Mon, 18 May 2026 16:58:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+May+18/26514823.html si-local-file:///var/storage/secattach/20260518/26514823.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+May+18/26514823.html Mon, 18 May 2026 16:58:00 -0400 CRVO O.00725545 http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html <p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing</em></p> <p align="center"><em>Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment</em></p> <p align="center"><em>Presented new analyses at AD/PD™ 2026 demonstrating that patients with lower plasma pTau181 levels, a biomarker indicating an earlier stage of disease and a low likelihood of having Alzheimer’s disease co-pathology, experienced greater clinical benefit from neflamapimod </em></p> <p>BOSTON, May 18, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/CervoMed+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Updates/26510175.html Mon, 18 May 2026 07:30:00 -0400 A.06822034 CRVO O.00725545 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CervoMed+Inc.+++++++++++++For%3A+Mar+31/26500602.html si-local-file:///var/storage/secattach/20260515/26500602.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CervoMed+Inc.+++++++++++++For%3A+Mar+31/26500602.html Fri, 15 May 2026 09:12:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CervoMed+Inc.+++++++++++++For%3A+Mar+31/26500602.html si-local-file:///var/storage/secattach/20260515/26500602.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CervoMed+Inc.+++++++++++++For%3A+Mar+31/26500602.html Fri, 15 May 2026 09:12:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CervoMed+Inc.++++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26467883.html si-local-file:///var/storage/secattach/20260511/26467883.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CervoMed+Inc.++++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26467883.html Mon, 11 May 2026 13:41:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CervoMed+Inc.++++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26467883.html si-local-file:///var/storage/secattach/20260511/26467883.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CervoMed+Inc.++++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26467883.html Mon, 11 May 2026 13:41:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CervoMed+Inc.+++++++++++++For%3A+Dec+31/26408085.html si-local-file:///var/storage/secattach/20260430/26408085.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CervoMed+Inc.+++++++++++++For%3A+Dec+31/26408085.html Thu, 30 Apr 2026 16:11:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CervoMed+Inc.+++++++++++++For%3A+Dec+31/26408085.html si-local-file:///var/storage/secattach/20260430/26408085.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++CervoMed+Inc.+++++++++++++For%3A+Dec+31/26408085.html Thu, 30 Apr 2026 16:11:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CervoMed+Inc.+++++++++++++For%3A+Jun+08/26402924.html si-local-file:///var/storage/secattach/20260430/26402924.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CervoMed+Inc.+++++++++++++For%3A+Jun+08/26402924.html Thu, 30 Apr 2026 10:18:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CervoMed+Inc.+++++++++++++For%3A+Jun+08/26402924.html si-local-file:///var/storage/secattach/20260430/26402924.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CervoMed+Inc.+++++++++++++For%3A+Jun+08/26402924.html Thu, 30 Apr 2026 10:18:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+Apr+22/26351392.html si-local-file:///var/storage/secattach/20260422/26351392.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+Apr+22/26351392.html Wed, 22 Apr 2026 16:08:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+Apr+22/26351392.html si-local-file:///var/storage/secattach/20260422/26351392.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CervoMed+Inc.+++++++++++++For%3A+Apr+22/26351392.html Wed, 22 Apr 2026 16:08:00 -0400 CRVO O.00725545 http://www.streetinsider.com/Press+Releases/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html <p align="center"><em>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible</em></p> <p align="center"><em>Findings also correlate with previously reported results on neflamapimod’s observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod’s potential to act on the underlying disease process in dementia with Lewy Bodies (DLB)</em></p> <p align="center"><em>DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments</em><em> in </em><em>the United States</em><em> or </em><em>European Union</em></p> <p>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 http://www.streetinsider.com/Press+Releases/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html Wed, 22 Apr 2026 07:30:00 -0400 CRVO O.00725545 http://www.streetinsider.com/Press+Releases/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html <p align="center"><em>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible</em></p> <p align="center"><em>Findings also correlate with previously reported results on neflamapimod’s observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod’s potential to act on the underlying disease process in dementia with Lewy Bodies (DLB)</em></p> <p align="center"><em>DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments</em><em> in </em><em>the United States</em><em> or </em><em>European Union</em></p> <p>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 http://www.streetinsider.com/Press+Releases/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html Wed, 22 Apr 2026 07:30:00 -0400 CRVO O.00725545 http://www.streetinsider.com/Globe+Newswire/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html <p align="center"><em>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible</em></p> <p align="center"><em>Findings also correlate with previously reported results on neflamapimod’s observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod’s potential to act on the underlying disease process in dementia with Lewy Bodies (DLB)</em></p> <p align="center"><em>DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments</em><em> in </em><em>the United States</em><em> or </em><em>European Union</em></p> <p>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 http://www.streetinsider.com/Globe+Newswire/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html Wed, 22 Apr 2026 07:30:00 -0400 CRVO O.00725545 http://www.streetinsider.com/Globe+Newswire/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html <p align="center"><em>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible</em></p> <p align="center"><em>Findings also correlate with previously reported results on neflamapimod’s observed effects on a blood biomarker of neurodegenerative disease activity, providing additional evidence of neflamapimod’s potential to act on the underlying disease process in dementia with Lewy Bodies (DLB)</em></p> <p align="center"><em>DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments</em><em> in </em><em>the United States</em><em> or </em><em>European Union</em></p> <p>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Today at the 2026 http://www.streetinsider.com/Globe+Newswire/CervoMed+Announces+New+Data+at+the+2026+AAN+Annual+Meeting+that+Demonstrated+Neflamapimod+Increased+Basal+Forebrain+Volume+and+Functional+Connectivity+in+Dementia+with+Lewy+Bodies/26347247.html Wed, 22 Apr 2026 07:30:00 -0400 CRVO O.00725545 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CervoMed+Inc.++++++++++++++++++++++++++Filed+by%3A+AWM+Investment+Company%2C+Inc./26283716.html si-local-file:///var/storage/secattach/20260407/26283716.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CervoMed+Inc.++++++++++++++++++++++++++Filed+by%3A+AWM+Investment+Company%2C+Inc./26283716.html Tue, 07 Apr 2026 16:25:00 -0400 CRVO O.00725545